Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas is viewed favorably because it is translating a differentiated protein-degradation platform into a diversified pipeline with multiple shots on goal, while de-risking capital needs through partnerships that provide upfront cash and future milestones. The VEPPANU deal with Rigel and Pfizer delivered $85M upfront plus up to $320M in milestones and 50/50 tiered royalties, removes a major commercial overhang, and supports reinvestment into wholly owned programs while management cites cash runway into 2H28. Fundamental upside is further supported by ARV-102’s >50% CSF LRRK2 degradation by day 14 with a clean safety profile, ARV-393’s early metabolic responses, and ARV-6723’s expected phase 1 start in mid-2026, giving investors multiple potential clinical catalysts.

Arvinas is facing substantial fundamental risk because its value depends on a small set of clinical-stage assets that could be halted or suspended by unfavorable trial data or regulatory refusal, leaving no approved products to support revenue. Its reliance on third-party CMOs adds execution risk that could bottleneck trials or commercialization, while intense competition in protein degradation and established breast cancer therapies may limit future uptake and pricing power. In addition, its patent portfolio can be challenged and the company needs reliable funding to advance assets through development, making access to capital a critical constraint that could delay or prevent profitability and cash flow generation.